Fmr LLC Has $46.03 Million Stock Holdings in Galapagos NV (NASDAQ:GLPG)

FMR LLC lowered its holdings in Galapagos NV (NASDAQ:GLPG - Free Report) by 44.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,598,912 shares of the biotechnology company's stock after selling 1,288,919 shares during the period. FMR LLC owned about 2.43% of Galapagos worth $46,033,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GLPG. Primecap Management Co. CA lifted its holdings in Galapagos by 0.7% during the 2nd quarter. Primecap Management Co. CA now owns 720,240 shares of the biotechnology company's stock worth $17,848,000 after buying an additional 5,000 shares during the last quarter. Stonepine Capital Management LLC raised its position in shares of Galapagos by 23.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company's stock worth $12,018,000 after purchasing an additional 91,366 shares during the period. Millennium Management LLC raised its position in shares of Galapagos by 5.3% during the 2nd quarter. Millennium Management LLC now owns 341,639 shares of the biotechnology company's stock worth $8,466,000 after purchasing an additional 17,089 shares during the period. Renaissance Technologies LLC raised its position in shares of Galapagos by 1.6% during the 2nd quarter. Renaissance Technologies LLC now owns 270,800 shares of the biotechnology company's stock worth $6,710,000 after purchasing an additional 4,300 shares during the period. Finally, DME Capital Management LP raised its position in shares of Galapagos by 46.9% during the 2nd quarter. DME Capital Management LP now owns 234,828 shares of the biotechnology company's stock worth $5,819,000 after purchasing an additional 75,000 shares during the period. Hedge funds and other institutional investors own 32.46% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on GLPG. Royal Bank of Canada lowered their target price on Galapagos from $32.00 to $30.00 and set a "sector perform" rating on the stock in a research report on Friday, November 1st. Leerink Partnrs upgraded Galapagos to a "hold" rating in a research report on Monday, September 9th. Kepler Capital Markets cut Galapagos from a "hold" rating to a "reduce" rating in a research report on Wednesday, November 20th. Finally, Leerink Partners began coverage on Galapagos in a research report on Monday, September 9th. They issued a "market perform" rating and a $24.00 target price on the stock. Two research analysts have rated the stock with a sell rating and six have issued a hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $30.75.

Galapagos Stock Up 0.1 %

Shares of GLPG stock traded up $0.04 during mid-day trading on Friday, hitting $26.99. 129,858 shares of the stock traded hands, compared to its average volume of 279,928. Galapagos NV has a twelve month low of $24.16 and a twelve month high of $42.46. The company's 50-day simple moving average is $28.17 and its 200-day simple moving average is $27.40.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.